FL-501 is a potential best in class antibody designed to neutralize GDF15 and prevent the binding to its receptor. FL-501 was engineered to have high affinity with improved half-life compared to other molecules of its class, which may result in significantly less frequent dosing. In pre-clinical models of cachexia increases in body weight have been observed following administration of the antibody.
In addition, FL-501 is expected to inhibit the activity of GDF15 in promoting an immunosuppressive tumor micro-environment in a broad range of cancers, including gastric, colorectal, pancreatic and prostate, where elevated GDF15 also correlates with poor prognosis.
GDF15 is secreted to blood stream at elevated levels
GDF15 overexpression leads to Cachexia
- Loss of
- Lower muscle
FL-501 prevents GDF15 from binding to GFRAL